[go: up one dir, main page]

PH12019502325A1 - Sustained release delivery systems comprising traceless linkers - Google Patents

Sustained release delivery systems comprising traceless linkers

Info

Publication number
PH12019502325A1
PH12019502325A1 PH12019502325A PH12019502325A PH12019502325A1 PH 12019502325 A1 PH12019502325 A1 PH 12019502325A1 PH 12019502325 A PH12019502325 A PH 12019502325A PH 12019502325 A PH12019502325 A PH 12019502325A PH 12019502325 A1 PH12019502325 A1 PH 12019502325A1
Authority
PH
Philippines
Prior art keywords
delivery systems
sustained release
drug delivery
release delivery
traceless linkers
Prior art date
Application number
PH12019502325A
Inventor
Christopher M Adams
Myriam April
Tanzina Fazal
Cornelia Jutta Forster
Edward Charles Hall
Cameron Chuck-Munn Lee
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62116508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12019502325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PH12019502325A1 publication Critical patent/PH12019502325A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
PH12019502325A 2017-04-20 2019-10-11 Sustained release delivery systems comprising traceless linkers PH12019502325A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487888P 2017-04-20 2017-04-20
PCT/IB2018/052740 WO2018193408A1 (en) 2017-04-20 2018-04-19 Sustained release delivery systems comprising traceless linkers

Publications (1)

Publication Number Publication Date
PH12019502325A1 true PH12019502325A1 (en) 2020-07-06

Family

ID=62116508

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502325A PH12019502325A1 (en) 2017-04-20 2019-10-11 Sustained release delivery systems comprising traceless linkers

Country Status (26)

Country Link
US (3) US10751417B2 (en)
EP (1) EP3612233A1 (en)
JP (1) JP7323453B2 (en)
KR (1) KR20190137888A (en)
CN (2) CN110603060A (en)
AR (1) AR111481A1 (en)
AU (1) AU2018255933B2 (en)
BR (1) BR112019021810A2 (en)
CA (1) CA3057590A1 (en)
CL (1) CL2019002969A1 (en)
CO (1) CO2019011577A2 (en)
CR (1) CR20190479A (en)
CU (1) CU20190082A7 (en)
DO (1) DOP2019000268A (en)
EA (2) EA202192099A3 (en)
EC (1) ECSP19075134A (en)
IL (1) IL269991B2 (en)
JO (1) JOP20190245A1 (en)
MA (1) MA50260A (en)
MX (1) MX2019012447A (en)
PE (2) PE20191837A1 (en)
PH (1) PH12019502325A1 (en)
SG (1) SG11201908740VA (en)
TW (1) TW201842935A (en)
UY (1) UY37686A (en)
WO (1) WO2018193408A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069782A (en) 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Charge ion channel blocker and how to use
CN117959415A (en) 2016-09-13 2024-05-03 阿勒根公司 Non-protein Clostridial toxin compositions
BR112019016139A2 (en) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company modified relaxin polypeptide comprising a pharmacokinetic enhancer and uses thereof
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
AR116566A1 (en) * 2018-10-03 2021-05-19 Novartis Ag SUSTAINED ADMINISTRATION OF ANGIOPOYETIN-SIMILAR POLIPEPTIDES 3
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
BR112021017772A2 (en) 2019-03-11 2021-11-16 Nocion Therapeutics Inc Charged ion channel blockers and methods for use
MX2021010869A (en) 2019-03-11 2022-01-19 Nocion Therapeutics Inc ESTER-SUBSTITUTED ION-CHANNEL BLOCKERS AND METHODS FOR THEIR USE.
EP3937945A4 (en) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2020254617A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254611A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254607A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
US11795320B2 (en) * 2019-09-20 2023-10-24 Bausch + Lomb Ireland Limited Grafted polymer and use thereof
WO2021091586A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2021091585A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN111110829A (en) * 2019-12-24 2020-05-08 浙江大学 Nanometer defensin gel scaffold and preparation method and application thereof
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4118070A4 (en) 2020-03-11 2024-04-10 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
CN111285736A (en) * 2020-04-09 2020-06-16 郑州先利达化工有限公司 Pesticide-fertilizer composition containing potassium phosphite, mineral potassium fulvate and polyglutamic acid
CA3179897A1 (en) * 2020-07-15 2022-01-20 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
CN114085290A (en) * 2020-08-25 2022-02-25 泰州迈博太科药业有限公司 Antibody prodrug, preparation method and application thereof
CN114129780B (en) * 2020-09-03 2022-06-28 天津大学 Preparation and application of a composite hydrogel for light-controlled release of nitric oxide
WO2023034299A1 (en) * 2021-08-31 2023-03-09 The Research Foundation For The State University Of New York Shear-thinning hydrogels and uses thereof
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CN115074402B (en) * 2022-07-20 2022-11-18 点滴(南京)生物科技有限公司 Gamma-sodium polyglutamate crosslinked hydrogel synthesized by enzyme method and synthesis method thereof
WO2024073588A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115947956B (en) * 2022-10-09 2024-03-19 西北农林科技大学 Pickering nanoemulsion based on bacterial cellulose nanocrystalline and application thereof
US12064467B2 (en) 2022-10-28 2024-08-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of humanin or other peptides
TW202430223A (en) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 Drug conjugates for the treatment of ocular disorders
TW202434299A (en) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 Methods of producing hydrogel microspheres
CN116236588A (en) * 2023-04-19 2023-06-09 山东大学 Application of azide-modified hyaluronic acid in drug delivery and/or drug storage
CN116253809B (en) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 A method for removing endotoxin from chitosan
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. New uses of omalizumab

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737523A1 (en) 1987-11-05 1989-05-18 Bayer Ag USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
ES2273415T3 (en) 1997-04-07 2007-05-01 Genentech, Inc. ANTI-VEGF ANTIBODIES.
EP1117444A2 (en) 1998-10-09 2001-07-25 The University Of Michigan Hydrogels and water soluble polymeric carriers for drug delivery
EP1358163A1 (en) 2001-01-23 2003-11-05 Eli Lilly And Company Melanocortin receptor agonists
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
MXPA06010782A (en) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Prodrug linker.
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US9290617B2 (en) 2005-07-06 2016-03-22 Molly S. Shoichet Method of biomolecule immobilization on polymers using click-type chemistry
US20070060658A1 (en) 2005-08-31 2007-03-15 Diaz David D Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
KR20080091180A (en) 2005-12-30 2008-10-09 파마이센시아 코퍼레이션 Drug-Polymer Conjugate
WO2007141309A2 (en) 2006-06-09 2007-12-13 Novartis Ag Stabilized insulin-like growth factor polypeptides
ITMI20061726A1 (en) 2006-09-11 2008-03-12 Fidia Farmaceutici CROSSLINKATI DERIVATIVES BASED ON HYALURONIC ACID RETICULATED VIA CLICK CHEMISTRY
EA016327B1 (en) 2007-02-09 2012-04-30 Айрм Ллк Compounds and compositions as channel activating protease inhibitors
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
AR065860A1 (en) 2007-03-29 2009-07-08 Novartis Ag 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
JPWO2009095954A1 (en) 2008-01-31 2011-05-26 アップサイド株式会社 DATA INPUT DEVICE, DATA INPUT METHOD, DATA INPUT PROGRAM, AND RECORDING MEDIUM CONTAINING THE SAME
EP2237799B1 (en) 2008-02-01 2019-04-10 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
CN110372792A (en) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 Inhibit the stabilization and soluble antibodies of VEGF
EP2352730A4 (en) 2008-11-07 2012-04-25 Lundbeck & Co As H BIOLOGICALLY ACTIVE AMIDES
JO3265B1 (en) 2008-12-09 2018-09-16 Novartis Ag Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
WO2010099818A1 (en) 2009-03-03 2010-09-10 Ao Technology Ag Thermoreversible polysaccharide hydrogel
WO2010102663A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Piperazine derivatives for use in therapy
IN2012DN00352A (en) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
BR112012000914B8 (en) 2009-07-14 2021-05-25 Irm Llc use of polypeptide with chondrogenic activity, in vitro method of inducing differentiation of mesenchymal stem cells into chondrocytes, and pharmaceutical composition for intra-articular application
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
MA33466B1 (en) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland INSULIN COMPOSITION WITH LONG TERM OF ACTION
BR112012002280B1 (en) * 2009-07-31 2020-04-07 Ascendis Pharma As water-insoluble hydrogel based on biodegradable polyethylene glycol, its preparation process, conjugate, vehicle-bound compound and pharmaceutical composition.
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
CN102686245B (en) 2009-10-29 2015-09-30 阿森迪斯药物股份有限公司 Disinfection of Biodegradable Hydrogels
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
MX2012011900A (en) 2010-04-15 2013-03-21 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates.
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
ES2823350T3 (en) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Heterocyclic compounds that activate AMPK and methods of using them
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
WO2012116250A1 (en) 2011-02-25 2012-08-30 University Of Massachusetts Medical School Monomers and polymers for functional polycarbonates and poly (ester-carbonates) and peg-co-polycarbonate hydrogels
CZ304072B6 (en) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amphoteric material based on crosslinked hyaluronic acid, process for its preparation, materials containing active agents enclosed in hyaluronate network, process for their preparation and their use
US20140256831A1 (en) 2011-05-31 2014-09-11 The University Of Tokyo Hydrogel and method for producing same
WO2012173952A1 (en) 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
KR20230107908A (en) 2011-06-21 2023-07-18 알닐람 파마슈티칼스 인코포레이티드 Angiopoietin-like 3(angptl3) irna compostions and methods of use thereof
US9872864B2 (en) 2011-08-12 2018-01-23 Ascendis Pharma A/S Sustained release composition of prostacyclin
MX358840B (en) 2011-09-07 2018-09-05 Prolynx Llc Hydrogels with biodegradable crosslinking.
US20130066063A1 (en) 2011-09-09 2013-03-14 John Cooke Hodges Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
HK1198631A1 (en) 2011-10-12 2015-05-22 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
JP2013116858A (en) 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Therapeutic medicine containing bdnf-like low molecular compound
AU2012344700A1 (en) 2011-12-01 2014-06-19 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
WO2013078564A2 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
EP2852664B1 (en) 2012-05-18 2017-09-06 Medical Research Council Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase.
MY178680A (en) 2012-10-11 2020-10-20 Ascendis Pharma As Hydrogel prodrugs
DK2906246T3 (en) * 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-Neutralizing Prodrugs Including Ranibizumab for the Treatment of Ocular Conditions Characterized by Ocular Neovascularization
AU2013328774B2 (en) 2012-10-11 2017-11-30 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
WO2014059446A1 (en) 2012-10-12 2014-04-17 Case Western Reserve University Biodegradable hydrogel for polynucleotide delivery
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
WO2014116717A1 (en) 2013-01-22 2014-07-31 Prolynx Llc Sealants having controlled degradation
SI2953976T1 (en) 2013-02-08 2021-08-31 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
UY35368A (en) 2013-03-08 2014-10-31 Irm Llc PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE
MA38369B1 (en) 2013-03-08 2018-10-31 Novartis Ag Peptides and compositions for the treatment of a lesion of the joint
KR20150131173A (en) 2013-03-15 2015-11-24 노파르티스 아게 Antibody drug conjugates
HK1221418A1 (en) 2013-04-22 2017-06-02 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
EP2988732B1 (en) 2013-04-22 2023-05-03 Ascendis Pharma A/S Modified hydrogels
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104292454B (en) 2013-07-17 2017-12-01 北京键凯科技股份有限公司 Polyethylene glycol cyclooctyne derivative
WO2015013165A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
EA201690278A1 (en) 2013-07-25 2016-06-30 Новартис Аг CYCLIC POLYPEPTIDES FOR TREATMENT OF HEART FAILURE
WO2015013167A1 (en) 2013-07-25 2015-01-29 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
JP2016172783A (en) 2013-08-08 2016-09-29 生化学工業株式会社 Structure swelling material
US20180042996A1 (en) 2013-10-08 2018-02-15 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-Linked IL-1ra Prodrug
WO2015061503A1 (en) 2013-10-22 2015-04-30 Prolynx Llc Conjugates of somatostatin and its analogs
CA2929201A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
EP3110450B1 (en) 2014-02-26 2023-06-07 University of Massachusetts Medical School Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016025752A1 (en) 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
TWI738632B (en) 2014-11-07 2021-09-11 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2018502868A (en) 2015-01-09 2018-02-01 アセンディス ファーマ グロース ディスオーダーズ エー／エス CNP prodrug
MA41794A (en) 2015-03-18 2018-01-23 The California Institute For Biomedical Res MODIFIED THERAPEUTIC AGENTS AND ASSOCIATED COMPOSITIONS
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
CN108463217A (en) 2015-11-20 2018-08-28 克里斯特递送有限公司 Nano particle with active targeting
KR20180129825A (en) 2016-03-16 2018-12-05 프로린크스 엘엘시 The extended release conjugate of exenatide analogs
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JOP20190245A1 (en) * 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers

Also Published As

Publication number Publication date
US20230201353A1 (en) 2023-06-29
RU2019136872A (en) 2021-05-21
US10751417B2 (en) 2020-08-25
US12433949B2 (en) 2025-10-07
RU2019136872A3 (en) 2021-08-31
EA201992484A1 (en) 2020-02-25
CO2019011577A2 (en) 2019-10-31
EA202192099A3 (en) 2022-02-28
BR112019021810A2 (en) 2020-05-26
PE20211281A1 (en) 2021-07-19
US20200376129A1 (en) 2020-12-03
CR20190479A (en) 2019-11-20
WO2018193408A1 (en) 2018-10-25
DOP2019000268A (en) 2020-02-16
IL269991B2 (en) 2023-07-01
SG11201908740VA (en) 2019-11-28
JOP20190245A1 (en) 2019-10-15
CN110603060A (en) 2019-12-20
CU20190082A7 (en) 2020-10-20
AU2018255933B2 (en) 2021-09-30
JP2020517623A (en) 2020-06-18
CN119185569A (en) 2024-12-27
AR111481A1 (en) 2019-07-17
US20180303945A1 (en) 2018-10-25
KR20190137888A (en) 2019-12-11
UY37686A (en) 2018-11-30
EP3612233A1 (en) 2020-02-26
ECSP19075134A (en) 2019-10-31
MA50260A (en) 2020-02-26
IL269991A (en) 2019-12-31
JP7323453B2 (en) 2023-08-08
CL2019002969A1 (en) 2020-02-07
MX2019012447A (en) 2020-01-13
AU2018255933A1 (en) 2019-10-17
TW201842935A (en) 2018-12-16
CA3057590A1 (en) 2018-10-25
IL269991B1 (en) 2023-03-01
EA202192099A2 (en) 2021-11-30
PE20191837A1 (en) 2019-12-30

Similar Documents

Publication Publication Date Title
PH12019502325A1 (en) Sustained release delivery systems comprising traceless linkers
PH12021550675A1 (en) Sustained delivery of angiopoetin-like 3 polypeptides
TW200500346A (en) HIV replication inhibiting indane substituted pyrimidines
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2017016802A (en) Pharmaceutical formulations.
MX2025012658A (en) Oseltamivir-containing pharmaceutical composition
ZA202104704B (en) Pharmaceutical composition
CL2018000339A1 (en) Combination treatment comprising the administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
ZA202003904B (en) Drug delivery system
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
IN2013MU03370A (en)
WO2020022976A3 (en) A formulation comprising dexketoprofen
MX2014005960A (en) Nitrogen-containing fused ring compounds for use as crth2 antagonists.
MX2022005932A (en) Prolonged release pharmaceutical compositions of ivabradine.
UA113436U (en) MEDICINE FOR TREATMENT OF ISCHEMIC TISSUE DAMAGES